Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal and How Do We Get There - Is RVD Good Enough?

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Amrita Krishnan
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Amrita Krishnan
139 views
October 17, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
18:26
William Schaffner

Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…

21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
17:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Highlights in 1L MM - Quadruplet Therapies …

Feat. A. Jakubowiak
16:42
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…

Feat. H. Hashmi
19:24
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Updates on Managing Newly Diagnosed MM - In…

Feat. P. Richardson
20:19
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …

Feat. A. Paulus
06:19
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Dara-KRd in NDMM Without ASCT - Final Analy…

Feat. B. Derman
49:01
Scripps MD Anderson Cancer Center

Current Summary of the Multiple Myeloma Treatment Landscape

Feat. R. Lu
12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
16:28
Total Health

Multiple Myeloma: A New Risk-Adapted Approach

Feat. J. Chandler
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
08:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Standard- and High-Risk ND Transplant-Eligi…

Feat. N. Joseph
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson
11:38
Heinz Ludwig

Maintenance Therapy in Myeloma: Which Agent and for How Long?

03:17
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Highlights From the International Myeloma S…

Feat. J. Richter
06:23
Integrity Continuing Education

ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VR…

Feat. O. Landgren
13:18
Insights from 2023 IMS Annual Meeting

Highlights and Key Takeaways From the 2023 International Myeloma Soc…

Feat. A. Jakubowiak
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
21:51
Moffitt Cancer Center

State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? Whe…

Feat. A. Grajales-Cruz
05:47
Meletios Dimopoulos

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…